At Secarna, we are flexible and can accommodate any meaningfully structured alliance across all stages of discovery and pre-clinical development.
Our flexible partnership model is set to accommodate the best mix of in-house and partner collaborations. Three typical structures are found in our partnership portfolio:
Program Licenses: Single asset deals to out-license high-value, non-core assets for further development and commercialization by partners
In-house development: High value programs progressed to pre-clinical proof-of-concept and first-in-human/early stage clinical studies followed by the potential out-licensing of these candidates to partners
Discovery & Research Alliances: Platform deals for broader discovery and development collaborations leveraging Secarna’s entire toolbox to generate partnered and co-owned ASO pipelines
Our objective is to become the partner-of-choice for antisense drug discovery and development programs and to form strategic partnerships fully leveraging our collaborators’ as well as our strengths.
Currently, we have a total of ten disclosed commercial partnerships.